List of insiders holdings for BeiGene Ltd.:
- Shares directly owned by the insider.
- Shares indirectly owned by the insider.
- Total shares owned by the insider (sum of shares directly and indirectly owned).
- Total market value if available.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Insider Holder Name | Report Date Time | Shares Owned Directly Indirectly | Total Shares Owned | Filing |
HHLR ADVISORS LTD. HILLHOUSE INVESTMENT MANAGEMENT LTD. 10% Owner | 2023-06-15 19:25:01 | 0 142,888,241 | 142,888,241 | Form 4 |
BAKER BROS. ADVISORS LP 14159 L.P. Baker Bros. Advisors (GP) LLC BAKER JULIAN BAKER FELIX 667 L.P. Baker Brothers Life Sciences LP Director 10% Owner | 2023-11-14 17:18:44 | 138,678,037 0 | 138,678,037 | Form 13D |
OYLER JOHN Chief Executive Officer | 2024-04-11 18:01:41 | 1,321,554 46,190,763 | 47,512,317 | Form 4 |
CB Biotech Investment Ltd CPEChina Fund L.P. CITIC PE Associates L.P. CITIC PE Funds Ltd 10% Owner | 2016-02-09 20:07:35 | 19,601,138 0 | 19,601,138 | Form 4 |
AMGEN INC 10% Owner | 2021-09-13 19:27:07 | 18,943,802 0 | 18,943,802 | Form 4 |
Wang Xiaodong Chair, Scientific Advisory Brd | 2023-12-04 17:44:13 | 5,459,438 5,358,962 | 10,818,400 | Form 4 |
BAKER BROS. ADVISORS LP 667 L.P. BAKER JULIAN BAKER FELIX Baker Bros. Advisors (GP) LLC Baker Brothers Life Sciences LP Director 10% Owner | 2023-11-14 17:54:26 | 20,838 9,878,124 | 9,898,962 | Form 4 |
Li Ji EVP and Gl. Head of Bus. Dev. | 2018-03-02 18:41:22 | 2,721,000 0 | 2,721,000 | Form 4 |
Glazer Donald W. Director | 2024-03-13 17:04:08 | 2,702,123 0 | 2,702,123 | Form 4 |
Peterson Amy C. CMO, Immuno-oncology | 2018-12-19 18:34:10 | 1,966,402 0 | 1,966,402 | Form 4 |
Wang Lai Global Head of R&D | 2023-06-27 17:24:09 | 1,600,027 58,188 | 1,658,215 | Form 4 |
Liang Howard CFO & Chief Strategy Officer | 2021-06-30 16:45:49 | 1,553,149 0 | 1,553,149 | Form 4 |
Wu Xiaobin President, COO & GM China | 2023-06-27 17:20:03 | 1,026,362 4000 | 1,030,362 | Form 4 |
Yang Jianxin Sr. VP, Head of Clinical Dev. | 2016-07-15 16:34:25 | 825,000 0 | 825,000 | Form 4 |
Yan Wendy Xiaojun Sr. VP, Head of Reg. Affairs | 2016-07-15 16:30:50 | 825,000 0 | 825,000 | Form 4 |
Huang Jane CMO, Hematology | 2021-12-16 17:50:15 | 371,331 0 | 371,331 | Form 4 |
Wang Julia Aijun Chief Financial Officer | 2024-03-04 17:22:09 | 320,086 0 | 320,086 | Form 4 |
Tang Ke Director | 2017-04-21 16:42:20 | 199,992 0 | 199,992 | Form 4 |
Lee Chan Henry SVP, General Counsel | 2023-08-02 17:10:36 | 171,314 0 | 171,314 | Form 4 |
Yuan RuiRong Chief Medical Officer | 2016-02-09 20:08:35 | 130,000 0 | 130,000 | Form 4 |
Malley Thomas Director | 2023-06-20 19:00:29 | 103,671 0 | 103,671 | Form 4 |
HOOPER ANTHONY C Director | 2023-06-20 18:59:10 | 64,389 0 | 64,389 | Form 4 |
Riva Alessandro Director | 2023-06-20 19:01:29 | 56,589 0 | 56,589 | Form 4 |
Dugan Margaret Director | 2023-06-20 18:56:55 | 56,589 0 | 56,589 | Form 4 |
Yi Qingqing Director | 2023-06-20 16:30:22 | 56,589 0 | 56,589 | Form 4 |
Ball Titus B. Principal Accounting Officer | 2024-03-26 17:26:42 | 38,155 0 | 38,155 | Form 3 |
Sanders Corazon (Corsee) D. Director | 2023-06-27 17:21:22 | 29,900 0 | 29,900 | Form 4 |
BRANDICOURT OLIVIER Director | 2024-03-04 17:24:47 | 27,794 0 | 27,794 | Form 4 |
Chen Timothy Yung-Cheng Director | 2021-06-21 16:42:08 | 25,298 0 | 25,298 | Form 4 |
su Jingshyh S Director | 2021-06-21 16:34:12 | 25,298 0 | 25,298 | Form 4 |
KRISHANA RANJEEV Director | 2016-02-02 19:14:15 | 0 0 | 0 | Form 3 |
GOLLER MICHAEL Director | 2016-02-02 19:40:27 | 0 0 | 0 | Form 3 |
Merck & Co. Inc. Merck Sharp & Dohme Corp. Merck Sharp & Dohme Research GmbH 10% Owner | 2018-02-13 16:29:07 | 0 0 | 0 | Form 13G |